{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:22:29Z","timestamp":1785219749605,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jgar.2024.06.008","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T23:46:26Z","timestamp":1719618386000},"page":"212-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-2179","authenticated-orcid":false,"given":"Bernardo Alfonso","family":"Martinez-Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"Xancal-Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Esteban-Kenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5677-3761","authenticated-orcid":false,"given":"Andrea Carolina","family":"Tello-Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bobadilla-del-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sifuentes-Osornio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2916","authenticated-orcid":false,"given":"Alfredo","family":"Ponce-de-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"Gonzalez-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.06.008_bib0001","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/IDR.S234610","article-title":"Antimicrobial resistance: implications and costs","volume":"12","author":"Dadgostar","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2024.06.008_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2024.06.008_bib0003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/21505594.2016.1159366","article-title":"Epidemiology of antimicrobial resistance in bloodstream infections","volume":"7","author":"Akova","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.jgar.2024.06.008_bib0004","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1060028014556652","article-title":"\u03b2-lactam\/\u03b2-lactamase inhibitor combinations: from then to now","volume":"49","author":"Toussaint","year":"2015","journal-title":"Annals Pharmacoth"},{"key":"10.1016\/j.jgar.2024.06.008_bib0005","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2020.115101","article-title":"Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens","volume":"98","author":"Pfaller","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.06.008_bib0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/acsinfecdis.7b00243","article-title":"Game changers: new \u03b2-lactamase inhibitor combinations targeting antibiotic resistance in gram-negative bacteria","volume":"4","author":"Bush","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jgar.2024.06.008_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00021-21","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2024.06.008_bib0009","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.jgar.2024.06.008_bib0010","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/jac\/dkt065","article-title":"Validation of carbapenemase and extended-spectrum \u03b2-lactamase multiplex endpoint PCR assays according to ISO 15189","volume":"68","author":"Bogaerts","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00533-18","article-title":"In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00934-22","article-title":"Ceftibuten-ledaborbactam activity against multidrug-resistant and extended-spectrum-\u03b2-lactamase-positive clinical isolates of Enterobacterales from a 2018-2020 Global Surveillance collection","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0013","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against gram-negative clinical isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0015","doi-asserted-by":"crossref","first-page":"1154.e9","DOI":"10.1016\/j.cmi.2019.01.003","article-title":"A novel framework to compare the effectiveness of \u03b2-lactamase inhibitors against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"25","author":"Abodakpi","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.06.008_bib0016","first-page":"131","article-title":"In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria","volume":"40","author":"Rawat","year":"2009","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.jgar.2024.06.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190910","article-title":"Febrile urinary-tract infection due to extended-spectrum beta-lactamase\u2013producing Enterobacteriaceae in children: a French prospective multicenter study","volume":"13","author":"Madhi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2024.06.008_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00144-19","article-title":"In vitro pharmacodynamics of a novel ceftibuten-clavulanate combination antibiotic against Enterobacteriaceae","volume":"63","author":"Grupper","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00145-19","article-title":"In vivo pharmacodynamic profile of ceftibuten-clavulanate combination against extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae in the murine thigh infection model","volume":"63","author":"Abdelraouf","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.06.008_bib0020","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s10096-018-3338-z","article-title":"Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series","volume":"37","author":"Cohen Stuart","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652400119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652400119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T09:42:38Z","timestamp":1726393358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652400119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"alternative-id":["S221371652400119X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.06.008","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}